ETFs positioned on Ipsen

Name YTD change Weight AuM
+11.20% - 27,154 M€
+7.22% - 92 M€
+12.57% - 13 M€
+6.23% - 49 M€
+0.94% - 51 M€
+12.09% - 66 M€
+11.61% - 24,432 M€
+9.76% - 75 M€
+9.73% - 67 M€
+8.66% - 6 M€
+5.89% - 1,193 M€
+8.21% - 6,576 M€
+11.73% - 3,469 M€
+8.93% - 5,871 M€
0.00%4.67% 8 M€
+65.98%3.96% 215 M€
+17.11%3.25% 23 M€
+16.65%1.94% 31 M€
+8.58%1.94% 31 M€
+2.68%1.75% 574 M€
+11.88%1.54% 18 M€
+12.72%1.52% 17 M€
+11.53%1.48% 160 M€
0.00%1.05% 208 M€
0.00%1.05% 26 M€
+11.17%0.98% 125 M€
+10.53%0.87% 730 M€
+10.50%0.83% 55 M€
+10.23%0.83% 20 M€
+28.08%0.79% 1,260 M€
+14.47%0.78% 103 M€
+10.84%0.59% 140 M€
+1.67%0.58% 38 M€
+9.12%0.54% 51 M€
+10.21%0.53% 40 M€
+7.13%0.5% 23 M€
+10.69%0.47% 937 M€
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535